Eton Pharmaceuticals, Inc. ETON

Eton Pharmaceuticals now holds exclusive commercialization rights for IMPAVIDO in the United StatesEton has integrated full Eton Cares® patient support, including $0 co-pay for eligible commercially insured patients and expanded patient assistance programsCentralized distribution through Anovo Specialty Pharmacy is designed to simplify access and therapy initiation for outpatient prescribing, inpatient consignment, and urgent access coordination DEER PARK, Ill., Sept. 28, 2026 (GLOBE NEWSWIRE) -

During the lightning round of the August 26 Mad Money episode, a caller asked whether it is time to “cut it off” or if Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has more potential given that they bought the shares at $30 and the stock is now above $60. In response, Jim Cramer said: I think you take […]

DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team will host 1x1 meetings on September 9, 2026 at the 2026 Wells Fargo Healthcare Conference being held September 8-10, 2026 in Boston, MA. To schedule a 1x1 meeting with the Company, please contact your

Biotech stock TG Therapeutics is building a cup base after a sell-off in early August. It is testing a key moving average.

These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months.

Eton Pharmaceuticals (ETON) has become a focus for investors after its second quarter 2026 report, which showed US$37.59 million in revenue, US$11.58 million in net income, and a shift from loss to earnings per share. See our latest analysis for Eton Pharmaceuticals. The strong Q2 results and raised 2026 guidance have coincided with a sharp re-rating in Eton Pharmaceuticals, with a 1 day share price return of 44.26% helping extend its year to date share price return to 261.99%, while the 3...

Eton stock catapulted to a record high Friday after the biotech company smashed second-quarter sales forecasts and hiked its guidance.

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index decreasing 0.4% a

Eton expects full-year 2026 revenue to exceed $145 million, up from its previous forecast of more than $120 million.

Moby summary of Eton Pharmaceuticals, Inc.'s Q2 2026 earnings call

Eton Pharmaceuticals Inc (ETON) reports a 99% revenue surge to $37.6 million, raises full-year guidance, and advances key pipeline assets.

Record revenue, with Q2 2026 product sales of $37.6 million, representing 99% growth over Q2 2025Q2 2026 fully diluted GAAP EPS of $0.35, non-GAAP fully diluted EPS of $0.43; EBITDA of $14.1 million, Adjusted EBITDA of $16.2 millionRaising full year revenue guidance, with 2026 revenue now expected to exceed $145 million, up from previous guidance of more than $120 millionRelaunched HEMANGEOL® May 1st, patient conversion completed ahead of scheduleAcquired late-stage product candidate ASN-001, ex